Literature DB >> 12052441

Sevoflurane suppresses noxious stimulus-evoked expression of Fos-like immunoreactivity in the rat spinal cord via activation of endogenous opioid systems.

Shuanglin Hao1, Osamu Takahata, Keiko Mamiya, Hiroshi Iwasaki.   

Abstract

We investigated the antagonism of sevoflurane antinociception by opioid antagonists in the rat formalin test. Formalin injection into the hindpaw of the rat induces the nocifensive flinching behavior and the expression of Fos-like immunoreactivity (Fos-LI) in the spinal cord. Sevoflurane significantly suppressed the flinching behavior and decreased the number of Fos-LI neurons in the dorsal horn of spinal cord compared with the control group. Moreover, pretreatment with intraperitoneal naloxone plus naltrexone antagonized the suppression of flinching behavior and the decrease of the number of Fos-LI neurons produced by 3% sevoflurane. Intraperitoneal opioid antagonists themselves had no effects on both the behavior response and the expression of Fos-LI induced by formalin injection. This study supports the hypothesis that sevoflurane suppresses the nociceptive response, at least in part, by activating endogenous opioid systems.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052441     DOI: 10.1016/s0024-3205(02)01704-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  Increases in mRNA and DREAM protein expression in the rat spinal cord after formalin induced pain.

Authors:  Idris Long; Rapeah Suppian; Zalina Ismail
Journal:  Neurochem Res       Date:  2010-12-25       Impact factor: 3.996

2.  Effects of transgene-mediated endomorphin-2 in inflammatory pain.

Authors:  Shuanglin Hao; Darren Wolfe; Joseph C Glorioso; Marina Mata; David J Fink
Journal:  Eur J Pain       Date:  2008-06-24       Impact factor: 3.931

3.  Gene transfer of glutamic acid decarboxylase reduces neuropathic pain.

Authors:  Shuanglin Hao; Marina Mata; Darren Wolfe; Shaohua Huang; Joseph C Glorioso; David J Fink
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

4.  Genetic Reporters of Neuronal Activity: c-Fos and G-CaMP6.

Authors:  Andrew E Hudson
Journal:  Methods Enzymol       Date:  2018-03-08       Impact factor: 1.600

5.  Differential effects of general anesthetics on anxiety-like behavior in formalin-induced pain: involvement of ERK activation in the anterior cingulate cortex.

Authors:  Cong Luo; Yan-Ling Zhang; Wei Luo; Fiona H Zhou; Chang-Qi Li; Jun-Mei Xu; Ru-Ping Dai
Journal:  Psychopharmacology (Berl)       Date:  2015-09-24       Impact factor: 4.530

6.  The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats.

Authors:  Shuanglin Hao; Shue Liu; Xuexing Zheng; Wenwen Zheng; Handong Ouyang; Marina Mata; David J Fink
Journal:  Neuropsychopharmacology       Date:  2010-11-10       Impact factor: 7.853

7.  REM sleep deprivation induces changes of down regulatory antagonist modulator (DREAM) expression in the ventrobasal thalamic nuclei of sprague-dawley rats.

Authors:  Rosfaiizah Siran; Asma Hayati Ahmad; Che Badariah Abdul Aziz; Zalina Ismail
Journal:  J Physiol Biochem       Date:  2014-09-15       Impact factor: 4.158

8.  Dual effects of intrathecal BAM22 on nociceptive responses in acute and persistent pain--potential function of a novel receptor.

Authors:  Yanguo Hong; Peifang Dai; Jianping Jiang; Xueai Zeng
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

9.  HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain.

Authors:  Shuanglin Hao; Marina Mata; Joseph C Glorioso; David J Fink
Journal:  Mol Pain       Date:  2006-02-17       Impact factor: 3.395

10.  Modulation of formalin-induced fos-like immunoreactivity in the spinal cord by swim stress-induced analgesia, morphine and ketamine.

Authors:  Ahmad Asma Hayati; Ismail Zalina; Than Myo; Abdul Aziz Che Badariah; Ahmad Azhar; Long Idris
Journal:  Ger Med Sci       Date:  2008-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.